Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes

Table 4 Comparison of clinical parameters between patients treated with daily DPP4 inhibitors or weekly omarigliptin

	FBG	IRI	HOMA-IR	HbA1c	BMI	log(hsCRP)	LDL-C	HDL-C	TG	RLP-C	AST	ALT	γGTP	eGFR	log(ACR)	SBP	DBP
Factor1.C.M	0.0822	0.0445*	0.0140*	0.735	0.217	0.00712*	0.0518	0.0579	0.0571	0.00701*	0.0593	0.0501	0.0627	0.673	0.588	0.0553	0.0818
Time	0.0318*	0.2124	0.0526	0.119	0.85	0.00077*	0.969	0.272	0.909	0.315	0.243	0.694	0.671	0.675	0.0235*	0.493	0.137
Factor1.C.M:Time	< 0.001*	< 0.001*	< 0.001*	0.029	0.465	< 0.001*	0.0891	0.476	0.0174*	< 0.001*	0.978	0.68	0.010*	0.531	< 0.001*	0.0707	0.741

FBG, fasting blood glucose; IRI, immunoreactive insulin; HOMA-IR, homeostatic model assessment of insulin resistance; HbA1c, hemoglobin, A1c; BMI, body mass index; hsCRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein choresterol; HDL-C, high-density, lipoprotein cholesterol; TG, triglyceride; RLP-C, remnant-like particle cholesterol; AST, aspartate aminotransferase; ALT, alanine, aminotransferase; γGTP, gamma-glutamyl transpeptidase; eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure
p values were presented
Factor 1 C.M (between-subject factor): group difference
Time (within-subject factor): time-dependent difference
Factor 1 C.M.: Time: interaction
Comparison for 12 months between patients treated with daily DPP4 inhibitors and weekly omarigliptin
* p < 0.05 with repeated measures ANOVA

ISSN: 1758-5996